

ASX RELEASE | OSTEOPORE LIMITED

Changes to Osteopore's Board of Directors

2 August 2021: Osteopore Limited (ASX: OSX) ("Osteopore" or the "Company"), a revenue-generating medical technology company that has commercialised a range of patented 3D printed bioresorbable products, today announces changes to its Board of Directors.

Osteopore wishes to advise that it has accepted the resignation of non-executive Chairman, Brett Sandercock, effective 01 August 2021. Mr Sandercock has been a valued member of the Board since June 2019, and his support was instrumental in the listing of the Company on the Australian Securities Exchange (ASX). Since listing, Mr Sandercock has continued to serve as non-executive Chairman and from this position has provided both strategic and operational guidance for the Company's growth. The Company would like to thank Mr Sandercock for his contributions and wishes him the very best for the future.

Appointment of Non-Executive Chairman and Independent Director

Coinciding with Mr Sandercock's resignation, Osteopore is pleased to announce that it has secured the experienced corporate executive Mark Leong as Chairman and Non-Executive Director. Mr Leong is a Fellow of the Association of Chartered Certified Accountants (ACCA), Chartered Accountant of the Institute of Singapore Chartered Accountants (ISCA) and Member of the Singapore Institute of Directors (SID). An Australian Permanent Resident with prior ASX board experience, Mr Leong has more than 22 years of corporate, management and directorship experience in a broad range of functions in a diverse range of industries having undertaken several C-suite roles (CEO, COO, & CFO) in several private as well as listed companies and presently serves as Independent Director in 3 Singapore listed companies. Currently primarily based in Singapore, and bringing a strong capital markets background and network in South-East Asian markets, Mr Leong is well placed to actively engage with and support the management team located in the Company's headquarters in Singapore, particularly given the current international travel restrictions between Singapore and Australia that exist as a result of COVID-19.

Osteopore has an active process of Board renewal and will continue to seek to expand the depth and breadth of its director skillsets and expertise.

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Carl Runde

Chief Financial Officer

Osteopore Limited

+61 400 118 017

carl_runde@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are made from proprietary polymer formulations, that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.